id: NEW:transoral_robotic_surgery_salvage_to_NEW:surgical_morbidity_head_neck
name: Transoral Robotic Surgery for Salvage Treatment â†’ Surgical Morbidity in Head
  and Neck Cancer
from_node:
  node_id: NEW:transoral_robotic_surgery_salvage
  node_name: Transoral Robotic Surgery for Salvage Treatment
to_node:
  node_id: NEW:surgical_morbidity_head_neck
  node_name: Surgical Morbidity in Head and Neck Cancer
direction: negative
category: healthcare_access
mechanism_pathway:
- 'Step 1: TORS provides minimally invasive transoral access to head and neck tumors,
  avoiding external incisions and tissue disruption associated with traditional open
  surgical approaches'
- 'Step 2: The robotic platform enables precise dissection in previously irradiated
  fields with enhanced visualization and instrument articulation, reducing collateral
  tissue damage'
- 'Step 3: Reduced surgical invasiveness leads to shorter tracheostomy dependence
  (mean 9.7 days to decannulation) and nasogastric tube dependence (mean 12.8 days),
  with only 0-11.5% requiring long-term tracheostomy'
- 'Step 4: Overall complication rate of 32.3% is achieved, with 92% of complications
  being lower severity (Clavien-Dindo grade 2-3), representing decreased morbidity
  compared to traditional open salvage techniques'
evidence:
  quality_rating: A
  n_studies: 15
  primary_citation: 'Sahil Goel et al. 2025. Is transoral robotic surgery useful as
    a salvage technique in head and neck cancers: a systematic review and meta analysis.
    Head & neck.'
  supporting_citations: []
description: Transoral robotic surgery (TORS) for salvage treatment of recurrent,
  residual, or second primary head and neck cancers in previously irradiated fields
  demonstrates reduced surgical morbidity compared to traditional open techniques.
  This systematic review and meta-analysis of 15 studies with 515 patients showed
  a pooled complication rate of 32.3%, with the majority (92%) being low-severity
  complications. Functional outcomes showed rapid recovery with mean tracheostomy
  decannulation at 9.7 days and nasogastric tube removal at 12.8 days, with minimal
  long-term feeding tube or tracheostomy dependence.
last_updated: '2025-12-02'
extraction_method: consolidated_batch_v3
quantitative_effects:
  effect_size:
    value: 0.323
    type: proportion
    ci_lower: null
    ci_upper: null
  p_value: null
  sample_size: 515
moderators:
- name: HPV status
  direction: strengthens
  strength: moderate
  description: HPV status identified as a confounding factor that may influence outcomes
    but not fully addressed in current literature
- name: Prior adjuvant therapy
  direction: weakens
  strength: moderate
  description: Previous radiation and chemotherapy exposure affects tissue healing
    and surgical outcomes in salvage setting
- name: Tumor stage/location
  direction: weakens
  strength: moderate
  description: More advanced tumors or challenging anatomic locations may have higher
    morbidity rates
